Telemark Asset Management LLC Has $11.04 Million Stock Position in RxSight, Inc. (NASDAQ:RXST)

Telemark Asset Management LLC increased its holdings in RxSight, Inc. (NASDAQ:RXST) by 6.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 321,000 shares of the company’s stock after acquiring an additional 20,000 shares during the period. Telemark Asset Management LLC’s holdings in RxSight were worth $11,036,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. RA Capital Management L.P. lifted its stake in RxSight by 6.0% in the 3rd quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company’s stock worth $193,609,000 after acquiring an additional 222,000 shares in the last quarter. State Street Corp lifted its stake in RxSight by 8.3% in the 3rd quarter. State Street Corp now owns 817,671 shares of the company’s stock worth $40,417,000 after acquiring an additional 62,349 shares in the last quarter. Geode Capital Management LLC lifted its stake in RxSight by 17.7% in the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after acquiring an additional 122,775 shares in the last quarter. Brown Capital Management LLC purchased a new stake in RxSight in the 3rd quarter worth about $26,813,000. Finally, Point72 Asset Management L.P. lifted its stake in RxSight by 610.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company’s stock worth $22,094,000 after acquiring an additional 384,041 shares in the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

RxSight Trading Up 2.5 %

RXST opened at $26.07 on Thursday. The stock has a market cap of $1.06 billion, a PE ratio of -31.41 and a beta of 1.22. RxSight, Inc. has a 1 year low of $24.64 and a 1 year high of $66.54. The stock’s 50 day simple moving average is $30.95 and its 200-day simple moving average is $41.52.

RxSight (NASDAQ:RXST) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.25). The firm had revenue of $40.21 million for the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. Equities analysts forecast that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on RXST shares. Needham & Company LLC reissued a “buy” rating and issued a $43.00 price objective on shares of RxSight in a research note on Wednesday, February 26th. Wells Fargo & Company cut their price target on RxSight from $40.00 to $35.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus cut their price target on RxSight from $35.00 to $33.00 and set a “hold” rating for the company in a research note on Wednesday, February 26th. UBS Group began coverage on RxSight in a research note on Friday, December 6th. They set a “buy” rating and a $52.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price target on RxSight from $62.00 to $40.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.63.

Insider Activity

In related news, Director Shweta Maniar sold 3,519 shares of the business’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $30.87, for a total value of $108,631.53. Following the sale, the director now owns 7,383 shares of the company’s stock, valued at $227,913.21. The trade was a 32.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jesse Anderson Corley purchased 1,443 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was bought at an average cost of $31.18 per share, for a total transaction of $44,992.74. Following the purchase, the director now owns 1,443 shares in the company, valued at $44,992.74. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 9.36% of the stock is currently owned by company insiders.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.